Antiretroviral therapy-induced Leber’s hereditary optic neuropathy by Moodley, A et al.
JUNE 2014, Vol. 15, No. 2   SAJHIVMED     69 
Optic neuropathy in HIV-infected patients results from the HIV infection itself, post-infectious auto-immune disease, 
opportunistic infections and drugs. Nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine and stavudine 
have known mitochondrial toxicity and can cause mitochondrial myopathies, neuropathies, hyperlactataemia, and can 
induce mitochondrial genetic disorders. Individuals with the mutation for Leber’s hereditary optic neuropathy (LHON), a 
mitochondrial disorder, are usually asymptomatic but develop visual loss when exposed to external triggers such as smoking. 
We report on two HIV-infected patients with LHON mutations (m.14484T>C and m.11778G>A) who developed profound 
visual loss with antiretroviral therapy. We postulate that the phenotypic expression of LHON in these genetically predisposed 
individuals was triggered by NRTI drugs lamivudine and tenofovir when used in combination, despite their relatively weak 
mitochondrial toxic effects. 
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Optic neuropathy in HIV disease is due to the 
virus itself, para-infectious disease, oppor-
tunistic infections, compression, raised intra-
cranial pressure or drug therapy.[1] Hence it is no 
surprise that visual loss from optic nerve disease 
is common in patients infected with HIV. Epidemiological 
studies are lacking, especially in South Africa (SA) where the 
prevalence of HIV is high. 
The causes of HIV-associated optic neuropathies that are 
commonly encountered in clinical practice are listed in Table 1. 
The immune-mediated optic neuropathies are para-infectious 
and occur in the setting of seroconversion or as part of acute 
disseminated encephalomyelitis when CD4+ counts may be 
relatively normal; these often respond to intravenous steroid 
therapy. Infectious and lymphomatous optic neuropathies 
occur during advanced stages of immunocompromise when 
CD4+ counts are low; in such patients, identifying an 
infective cause is urgent to prevent blindness. Ethambutol-
associated retrobulbar optic neuropathy is common, especially 
in disseminated tuberculosis where its prolonged use over 
9 months is advocated.
The optic nerve is unique as it is a white matter tract 
that is particularly susceptible to physical, ischaemic, toxic 
and hypoxic insults due to: its relatively large diameter 
(1.2 million axons per nerve); its intra- and extra-cranial 
location; its myelinated and unmyelinated segments; and the 
high energy demand by the retinal ganglion cells.[2] The large 
accumulation of mitochondria within the optic nerve head 
is mostly responsible for its energy supply.[3] The function 
of these mitochondria is disturbed in the setting of Leber’s 
hereditary optic neuropathy (LHON), where gene defects from 








Table 1. Common causes of HIV-associated 
optic neuropathy
Immune mediated
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cause optic nerve dysfunction in over 95% of 
patients by disrupting complex I-dependent 
adenosine triphosphate synthesis. The ab normal 
mitochondrial gene is maternally inherited 
with incomplete penetrance, as only 50% of 
males with the LHON mitochondrial muta tion 
present with the disorder. [4] Expression of the 
disease occurs when triggered by environ mental 
factors such as smoking, alcohol and acute 
illness. The typical presentation is sequential 
or bilateral, simultaneous central visual loss in 
the 2nd to 3rd decade of life in males carrying 
one of the LHON mitochondrial mis-sense 
mutations. Ten per cent of female carriers are 
symptomatic. There is initial disc swelling and 
circumpapillary telangiectasia, which within 
a few months are replaced by optic atrophy 
from axonal loss. Visual loss and centro-caecal 
scotomas progress over months to years. 
Idebenone, a co-enzyme Q10 derivative, has 
shown promise in delaying the progression 
of illness and in some cases substantially 
reversing the visual and field loss.[5]
We present two patients from our neuro-
ophthalmology unit who presented with 
central visual loss after starting antiretroviral 
therapy containing tenofovir, lamivudine and 
efavirenz. 
Patient 1 
A 31-year-old HIV-infected man presented 
with a 4-month history of gradual and pro-
gressive loss of bilateral vision. He denied 
having headaches, pain on eye movements or 
constitutional symptoms. He was previously 
unemployed. Two years before, he acquired 
pulmonary tuberculosis and was found to 
be HIV-infected; he was then prescribed 
tenofovir, lamivudine and efavirenz. He had 
a four pack-year smoking history, did not 
consume alcohol and had no family history of 
visual loss.
His visual acuity was ‘counting fingers’ 
on the right and ‘hand movements’ on the 
left. Central field defects were detected bi -
laterally on confrontation, but were globally 
lost on automated Humphrey visual field 
(HVF) testing. Colour vision was severely 
impaired bilaterally (0/15 on Ishihara pseudo-
isochromatic plates). Both pupils were sluggishly 
reactive and severe bilateral optic atrophy was 
present on funduscopy (Fig. 1). The visual 
evoked potential (VEP) P100 waveforms were 
obtainable bilaterally using goggles, but were 
markedly reduced in amplitude. 
Magnetic resonance imaging (MRI) of the 
brain and orbits was normal. Chest radiograph 
and cerebrospinal fluid (CSF) exam-
ination, including neurotropic virus (cyto-
megalovirus, herpes simplex viruses 1 and 2, 
varicella zoster virus, Epstein-Barr virus 
and John Cunningham virus) testing were 
unremarkable and routine haematological 
investigations were normal. His vitamin B12, 
folate and iron levels were normal. CD4+ 
cell count was 746  cells/µl and viral load 
was undetectable. The antinuclear factor 
(ANF), antineutrophil cytoplasmic antibody 
(ANCA), rapid plasma reagin (RPR) and 
rheumatoid factor (RF) were negative, and 
serum angiotensin converting enzyme (SACE) 
was 19  U/l. Oligoclonal bands (OBs) were 
not detected in the CSF and aquaporin 4 
antibodies were negative. He tested positive 
for the 14484T>C mitochondrial mutation 
associated with LHON.
Patient 2
A 33-year-old HIV-infected man who worked 
in construction presented with bilateral visual 
loss over the previous 3 years. He had been 
diagnosed with HIV infection after voluntary 
testing and prescribed tenofovir, lamivudine 
and efavirenz 3 months before the onset of 
his visual symptoms. He first noticed loss 
of central vision in the left eye, followed by 
similar symptoms in the right a month later. 
He denied any colour desaturation and pain 
on eye movements, but did notice intermittent 
oscillopsia at the onset of his symptoms. He 
had no other medical history of note and 
denied any smoking or alcohol use, exposure 
to any toxins or substance abuse. He had no 
family history of visual loss.
His visual acuity bilaterally was ‘counting 
fingers’. Central scotomas were noted on con-
frontation, but HVF showed bilateral, inferior 
altitudinal field defects. Colour vision was 
severely impaired (0/15 on Ishihara pseudo-
isochromatic plates) and funduscopy revealed 
bilateral profound optic atrophy (Fig. 2). His 
pupils were reactive and a 1+ relative afferent 
pupillary defect was present on the right. 
The rest of his neurological examination 
was normal, and standard haematological, 
biochemical and CSF examination tests were 
normal. His CD4+ count was 615 cells/µl 
and viral load was 27 copies/ml. MRI of the 
brain and orbits was normal, as was his chest 
radiograph. The VEP P100 wave amplitudes 
were reduced bilaterally. His vitamin B12 level 
was mildly reduced at 117 pmol/l (normal 133 
- 675), serum folate was normal and SACE was 
Fig. 1. Funduscopy of patient 1, showing bilateral optic atrophy and normal retinas.
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27 U/l. ANF, ANCA, RF, RPR, human T lymphotropic virus 1, CSF OB 
and aquaporin 4 antibodies were negative. He tested positive for the 
11778G>A mitochondrial mutation associated with LHON.
Discussion
Genetic testing of LHON by polymerase chain reaction and restriction 
enzyme analysis is offered by the Inherited Metabolic Disease 
Laboratory, National Health Laboratory Service, based at Groote Schuur 
Hospital in Cape Town. All six LHON mutations in mitochondrial 
DNA are screened for, viz. m.14484T>C, m.11778G>A, m.3460G>A, 
m.14459G>A, m.14482C>G, and m.14487T>C. Both patients had a 
common mitochondrial mutation associated with LHON. Patient 1 was 
a smoker without a significant pack-year history and patient 2 had mild 
vitamin B12 deficiency, neither of which seemed to have contributed 
significantly as triggers for LHON, or to the visual loss on a toxic or 
nutritional basis. Both patients, however, were HIV-positive, developed 
their symptoms some time after starting ART and were not on other 
medication that could have contributed to visual impairment.
LHON following the introduction of the strongly mitochondrial 
toxic nucleoside reverse transcriptase inhibitors (NRTIs) zidovudine, 
stavudine and zalcitabine (ddC) has previously been reported in patients 
with the mitochondrial mutations 11778G>A and 14484T>C.[6-8] No 
cases have been described with the weaker mitochondrial toxic NRTI 
drugs tenofovir and lamivudine until now. The catastrophic sequela 
of lactic acidosis that occurs with zidovudine and stavudine, however, 
is less likely to occur with the tenofovir-lamivudine combination. 
Tenofovir is a less toxic agent than zidovudine, didanosine, stavudine 
and zalcitabine, and does not usually cause lactic acidosis, myopathy 
and peripheral neuropathy. Its mechanism of action, like the other 
NRTIs, is mitochondrial DNA polymerase inhibition, and thus it is 
not devoid of toxic effects. Tenofovir-induced nephropathy occurs 
on the basis of mitochondrial toxicity within the kidneys’ proximal 
tubular cells, which are rich in mitochondria.[9] Irregularly shaped 
mitochondria with fragmented cristae ensue. There are currently 
no data on the effects of tenofovir on the mitochondria of the optic 
neurons and retina. However, an analogous mechanism of toxicity 
at the optic nerve head, which also has abundant mitochondria, is 
conceivable with tenofovir. However, based on existing evidence, the 
role of lamivudine in mitochondrial toxicity is less clear. Hence, we 
postulate that in the genetically susceptible individual, tenofovir has the 
potential to trigger LHON.
Idebenone (co-enzyme Q10 derivative) is not available in SA. 
However, co-enzyme Q10 is available as an over-the-counter 
preparation at most pharmacies. Both patients were treated with this 
formulation and have not shown any deterioration or improvement 
after 6 months of treatment. ART was discontinued in both patients 
and when required, both patients will be considered for a combination 
of antiretrovirals with lower mitochondrial toxicities, such as protease 
and integrase inhibitors.
Conclusion
LHON can be triggered by NRTIs in HIV-infected patients who har bour 
the LHON mutations. The expression of LHON can occur regardless 
of the mitochondrial toxic potential of ART. The routine screening 
for LHON mutations on all asymptomatic male patients about to 
commence NRTIs is not cost effective. However, the progression of 
LHON is reasonably manageable with appropriate therapy; hence test-
ing for LHON mutations in HIV-positive patients with optic neuropathy 
who are on ART should become standard practice. 
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